1. Home
  2. CSTL vs MQY Comparison

CSTL vs MQY Comparison

Compare CSTL & MQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$35.31

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Logo Blackrock MuniYield Quality Fund Inc.

MQY

Blackrock MuniYield Quality Fund Inc.

N/A

Current Price

$9.94

Market Cap

787.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
MQY
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
787.3M
IPO Year
2019
1994

Fundamental Metrics

Financial Performance
Metric
CSTL
MQY
Price
$35.31
$9.94
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $45.11
N/A
AVG Volume (30 Days)
254.6K
★ 949.1K
Earning Date
11-02-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $344,229,000.00
N/A
Revenue This Year
$8.41
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.66
N/A
52 Week Low
$17.72
$9.80
52 Week High
$44.28
$11.94

Technical Indicators

Market Signals
Indicator
CSTL
MQY
Relative Strength Index (RSI) 63.06 25.31
Support Level $33.90 N/A
Resistance Level $36.85 $11.53
Average True Range (ATR) 1.46 0.15
MACD -0.07 -0.03
Stochastic Oscillator 86.78 20.99

Price Performance

Historical Comparison
CSTL
MQY

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About MQY Blackrock MuniYield Quality Fund Inc.

Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.

Share on Social Networks: